natgillin/translations-raw huggingface dataset:
When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76 - 100 %. 
Če se je zdravljenje z lamivudinom nadaljevalo po transplantaciji, je prišlo do zmanjšanja reinfekcij presadka s HBV, izginotje HBsAg je poraslo, stopnja enoletnega preživetja pa je bila med 76 in 100 %.
Rhabdomyolysis * In Phase III studies frequency observed in the lamivudine treatment group was not greater than observed in the placebo group 
* V študijah III. faze pogostnost v skupini z lamivudinom ni bila večja od pogostnosti v skupini s placebom.
The mean lamivudine CSF/serum concentration ratio 2-4 hours after oral administration was approximately 0.12. 
Povprečno razmerje CSF/serum koncentracij lamivudina 2 do 4 ure po peroralnem vnosu je bilo približno 0,12.
1 Remove the child-proof bottle cap (A). 
1 Odstranite za otroke varno zaporko stekleničke (A).
Other side effects Other side effects have occurred in a very small number of people but their exact frequency is unknown 
Ostali neželeni učinki so se pojavili pri zelo majhnem številu bolnikov, vendar njihova natančna pogostnost ni znana:
ULN = Upper limit of normal. 
ZMN = zgornja meja normale
Contents of the pack and other information What Zeffix contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Zeffix
Lamivudine-TP acts as a substrate for the HBV viral polymerase. 
Lamivudin-TP deluje kot substrat za HBV virusno polimerazo.
The solution is clear, colourless to pale yellow in colour with strawberry/banana flavouring. 
Peroralna raztopina je bistra, brezbarvna do bledo rumena raztopina z aromo jagode/banane.
Experience in patients with decompensated liver disease Placebo controlled studies have been regarded as inappropriate in patients with decompensated liver disease, and have not been undertaken. 
Izkušnje pri bolnikih z dekompenzirano jetrno boleznijo S placebom nadzorovane študije pri bolnikih z dekompenzirano jetrno boleznijo se smatrajo kot neprimerne, zato niso bile izvedene.
Boxes containing 28 or 84 film-coated tablets in double foil blisters, laminated with polyvinyl chloride. 
Škatle, ki vsebujejo 28 ali 84 filmsko obloženih tablet v pretisnem omotu, prevlečenem s polivinilkloridom.
If you accidentally take too much, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice. 
Če po nesreči vzamete prevelik odmerek, se za dodatni nasvet obrnite na svojega zdravnika ali farmacevta ali pa na urgentni oddelek najbližje bolnišnice.
Substances shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with lamivudine. 
Malo je verjetno, da bi učinkovine, za katere se je izkazalo, da se primarno izločajo bodisi preko aktivne organske anionske poti bodisi z glomerularno filtracijo, povzročile klinično pomembne interakcije z lamivudinom.
See section 3 for more information about how to take Zeffix. 
Glejte poglavje 3 za nadaljnja navodila v zvezi z jemanjem zdravila Zeffix.
The standard recommended procedures for hepatitis B virus immunisation in infants should be followed. 
Slediti je treba standardnim priporočenim postopkom za imunizacijo otrok proti hepatitisu B.
Frequency of emergence of YMDD mutant HBV and impact on the treatment response Lamivudine monotherapy results in the selection of YMDD mutant HBV in approximately 24 % of patients following one year of therapy, increasing to 69 % following 5 years of therapy. 
Pogostnost pojava YMDD mutanta in vpliv na odziv na zdravljenje Monoterapija z lamivudinom privede do selekcije YMDD mutanta HBV pri približno 24 % bolnikov po enem letu zdravljenja in po 5-ih letih zdravljenja naraste do 69 %.
• if you're allergic to lamivudine or to any of the other ingredients of this medicine (listed in 
• če ste alergični na lamivudin ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju
100 mg once daily, Cmax is in the order of 1.1-1.5 µg/ml and trough levels were 0.015-0.020 µg/ml. 
Pri vrednostih terapevtskega odmerka, npr. 100 mg enkrat dnevno, se Cmax giblje v intervalu med 1,1 in 1,5 μg/ml, najnižje koncentracije pa so 0,015 do 0,020 μg/ml.
Continued lamivudine treatment for an additional 2 years in patients who had failed to achieve HBeAg seroconversion in the initial 1 year controlled studies resulted in further improvement in bridging fibrosis. 
Nadaljevanje zdravljenja z lamivudinom še dodatni 2 leti je pri bolnikih, pri katerih v začetnih enoletnih nadzorovanih študijah ni prišlo do serokonverzije HBeAg, privedlo do nadaljnjega izboljšanja fibroze.
Zeffix contains sugar and preservatives 
Zdravilo Zeffix vsebuje sladkor in konzervanse
Forty patients (HBeAg negative or HBeAg positive) with either decompensated liver disease or recurrent HBV following liver transplantation and YMDD mutant were enrolled into an open label arm of study NUC20904. 
Štirideset bolnikov (HBeAg negativni ali HBeAg pozitivni) z dekompenzirano jetrno boleznijo ali rekurentnim HBV po transplantaciji jeter in YMDD mutantom je bilo prav tako vključenih v odprti del študije NUC20904.
Use the oral applicator supplied with the pack to measure your dose accurately (see also Section 3). 
Za točno merjenje odmerka uporabite peroralni aplikator, ki je priložen v pakiranju (glejte tudi poglavje 3).
Lamivudine had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole. 
Lamivudin nima učinka na farmakokinetiko trimetoprima ali sulfametoksazola.
Lamivudine is metabolised by both infected and uninfected cells to the triphosphate (TP) derivative which is the active form of the parent compound. 
Lamivudin se presnavlja tako v okuženih kot v neokuženih celicah v trifosfatni derivat (TP), ki je aktivna oblika izvorne učinkovine.
If lamivudine is discontinued, patients should be periodically monitored for evidence of recurrent hepatitis (see section 4.4). 
Če se zdravljenje lamivudinom prekine, je treba bolnike periodično nadzirati glede dokazov rekurentnega hepatitisa (glejte poglavje 4.4).
The pack also includes a polyethylene applicator-adapter, and a 10 ml oral applicator comprised of a polypropylene barrel (with ml graduations) and a polyethylene plunger. 
Škatli je priložen tudi polietilenski nastavek za aplikator in 10 ml peroralni aplikator, ki vsebuje polipropilensko cev (z mililitersko lestvico) in polietilenskim batom.
15 to < 30 
15 do < 30
HBeAg seroconversion 
Serokonverzija HBeAg
Dose reduction in patients with a creatinine clearance of < 50 ml/min is necessary (see section 4.2). 
Pri bolnikih z očistkom kreatinina < 50 ml/min je treba odmerek zmanjšati (glejte poglavje 4.2).
For the treatment of patients who are co-infected with HIV and are currently receiving or plan to receive treatment with lamivudine or the combination lamivudine-zidovudine, the dose of lamivudine prescribed for HIV infection (usually 150 mg/twice daily in combination with other antiretrovirals) should be maintained. 
Pri zdravljenju bolnikov, ki so sočasno okuženi z virusom HIV in se trenutno že zdravijo ali pa se zanje načrtuje zdravljenje z lamivudinom ali kombinacijo lamivudin-zidovudin, je potreben vzdrževalni odmerek lamivudina, ki je predpisan za okužbo z virusom HIV (običajno 150 mg/dvakrat dnevno v kombinaciji z drugimi protiretrovirusnimi zdravili).
Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied. 
Ker se lamivudin izloča z dializo, se v primeru prevelikega odmerjanja lahko uporabi kontinuirana hemodializa, vendar pa to še ni preučeno.
Due to the marginal liver function in these patients, hepatitis reactivation at discontinuation of lamivudine or loss of efficacy during treatment may induce severe and even fatal decompensation. 
Zaradi mejne funkcijske sposobnosti jeter pri takšnih bolnikih lahko ponoven zagon hepatitisa ob prekinitvi zdravljenja z lamivudinom ali izgubi učinkovitosti med zdravljenjem sproži hudo in celo smrtno dekompenzacijo.
These medicines should not be used with Zeffix: 
Zdravila, ki se ne smejo uporabljati skupaj z zdravilom Zeffix:
Table 2: Efficacy results 5 years by YMDD status (Asian Study) NUCB3018 
Preglednica 2: Rezultati učinkovitosti v 5 letih glede na status YMDD (Azijska študija)
Butterscotch coloured, film-coated, capsule shaped, biconvex, approximate dimensions 11mm x 5mm and engraved “GX CG5” on one face. 
Karamelne barve, filmsko obložena, v obliki kapsule, bikonveksna, približne dimenzije 11 mm x 5 mm, z na eni strani vtisnjeno oznako “GX CG5”.
The dosage should, therefore, be reduced for patients with a creatinine clearance of < 50 ml/minute. 
Tako je treba pri bolnikih z očistkom kreatinina < 50 ml/minuto odmerek zmanjšati.
3 Abbott Genostics solution hybridisation assay (LLOD < 1.6 pg/ml 4 Chiron Quantiplex assay (LLOD 0.7 Meq/ml) 
Abbott Genostics hibridizacijski test v raztopini (LLOD < 1,6 pg/ml) Chiron Quantiplex test (LLOD 0,7 Meq/ml)
If overdose occurs the patient should be monitored and standard supportive treatment applied as required. 
V primeru prevelikega odmerjanja je treba bolnika nadzirati in po potrebi uvesti standardno podporno zdravljenje.
Other medicines and Zeffix 
Druga zdravila in zdravilo Zeffix
Exacerbations in patients with decompensated cirrhosis Transplantation recipients and patients with decompensated cirrhosis are at greater risk from active viral replication. 
Prejemniki presajenih organov in bolniki z dekompenzirano cirozo so v večji nevarnosti glede aktivne replikacije virusa.
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients. 
Pojavnost neželenih učinkov in laboratorijskih abnormalnosti (z izjemo zvišanja ALT in CPK, glejte spodaj) je bila podobna pri bolnikih, ki so se zdravili s placebom in pri bolnikih, ki so se zdravili z lamivudinom.
Pharmacotherapeutic group - Antivirals for systemic use, nucleoside and nucleotide reverse transcriptase inhibitors, ATC Code: J05AF05. 
Farmakoterapevtska skupina:Zdravila za sistemsko zdravljenje virusnih infekcij, nukleozidni in nukleotidni inhibitorji reverzne transkriptaze, oznaka ATC: J05AF05.
In patients with chronic hepatitis B there was no observed difference in incidence of these events between placebo and lamivudine treated patients. 
Pri bolnikih s kroničnim hepatitisom B niso opazili razlik v pojavnosti teh dogodkov, če so bili bolniki zdravljeni s placebom ali lamivudinom.
Normalisation of ALT levels occurred in 31 % (14/45) of patients receiving combined therapy versus 6 % (3/47) receiving lamivudine alone. 
Normalizacija vrednosti ALT se je pojavila pri 31 % (14/45) bolnikov, ki so imeli kombinirano zdravljenje, v primerjavi s 6 % (3/47) pri tistih, ki so prejemali samo lamivudin.
The oral applicator is provided for accurate measurement of the prescribed dose of oral solution. 
Za natančno odmerjanje predpisanega odmerka peroralne raztopine je priložen peroralni aplikator.
This will mean taking blood samples to check for any raised liver enzyme levels, which may indicate liver damage. 
Jemal vam bo vzorce krvi in preverjal morebitne povišane vrednosti jetrnih encimov, ki lahko kažejo na okvaro jeter.
Data is available from an extended treatment study in HBeAg negative patients (NUCAB3017) treated with lamivudine. 
Podatki so na voljo iz študije s podaljšanim zdravljenjem (NUCAB3017) pri HBeAg negativnih bolnikih, ki so se zdravili z lamivudinom.
The pack includes an oral applicator with ml graduations and an applicator-adapter, which should be fitted to the bottle before use. 
Škatli je priložen peroralni aplikator z merilno skalo v ml in nastavek za aplikator, ki ga je treba pred uporabo namestiti na plastenko.
Some lateonset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). 
Opisane so nekatere nevrološke motnje s poznim nastankom (hipertonija, konvulzije, nenormalno vedenje).
Zidovudine had no effect on the pharmacokinetics of lamivudine (see section 5.2). 
Zidovudin ni imel učinka na farmakokinetiko lamivudina (glejte poglavje 5.2).
Renal clearance accounts for about 70 % of lamivudine elimination. 
Približno 70 % izločenega lamivudina gre na račun ledvičnega očistka.
What you need to know before you take Zeffix 3. 
Kaj morate vedeti, preden boste vzeli zdravilo Zeffix 3.
• a decrease in the number of cells involved in blood clotting (thrombocytopenia). 
• zmanjšanje števila celic, ki sodelujejo pri strjevanju krvi (trombocitopenija).
Interactions with other medicinal products 
Interakcije z drugimi zdravili
The tablets are butterscotch coloured, capsule shaped, biconvex and engraved “GX CG5” on one side. 
Tablete so karamelne barve, v obliki kapsule, bikonveksne in imajo na eni strani vtisnjeno oznako “GX CG5”.
Lamivudine is predominantly eliminated by active organic cationic secretion. 
Lamivudin se pretežno izloča z aktivno sekrecijo organskih kationov.
What Zeffix is and what it is used for 
Kaj je zdravilo Zeffix in za kaj ga uporabljamo
The bottle contains 240 ml of lamivudine solution (5 mg/ml). 
Plastenka vsebuje 240 ml raztopine lamivudina (5 mg/ml).
Administration of trimethoprim/sulphamethoxazole 160 mg/800 mg increased lamivudine exposure by about 40 %. 
Dajanje 160 mg/800 mg trimetoprima/sulfametoksazola je izpostavljenost lamivudinu zvečalo za 40 %.
The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo. 
Odstotek bolnikov, ki so imeli zvišane vrednosti ALT po zdravljenju v povezavi s povečanjem nivoja bilirubina, je bil nizek in podoben pri bolnikih, ki so jemali ali lamivudin ali placebo.
- Week 260 4 negative positive < baseline positive > baseline 
- 260. teden4 negativna pozitivna < izhodiščna vrednost pozitivna > izhodiščna vrednost
When possible, avoid chronic co-administration of Zeffix with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). 
Če je mogoče, se izognite kronični sočasni uporabi zdravila Zeffix z zdravili, ki vsebujejo sorbitol ali druge osmotsko delujoče polialkohole oziroma monosahardine alkohole (npr. ksilitol, manitol, laktitol, maltitol).
However, the proportion of patients who had post-treatment elevations associated with bilirubin elevations was low and similar in both treatment arms (see Table 3 in section 5.1). 
Toda delež bolnikov, ki se jim je po zdravljenju pojavilo zvišanje skupaj z zvišanjem bilirubina, je bil majhen in v obeh terapevtskih krakih podoben (glejte preglednico 3 v poglavju 5.1).
Sucrose 20 % w/v (4 g/20 ml) Methyl parahydroxybenzoate (E218) 1.5 mg/ml Propyl parahydroxybenzoate (E216) 0.18 mg/ml 
saharoza 20 % w/v (4 g/20 ml) metilparahidroksibenzoat (E218) 1,5 mg/ml propilparahidroksibenzoat (E216) 0,18 mg/ml
These patients should be monitored for clinical, virological and serological parameters associated with hepatitis B, liver and renal function, and antiviral response during treatment (at least every month), and, if treatment is discontinued for any reason, for at least 6 months after treatment. 
Pri takšnih bolnikih je treba nadzirati klinične, virološke in serološke parametre, povezane s hepatitisom B, jetrno in ledvično funkcijo ter protivirusni odgovor med zdravljenjem (vsaj mesečno), v primeru prekinitve zdravljenja iz kateregakoli razloga pa še vsaj 6 mesecev po zdravljenju.
If you have further questions, ask your doctor or pharmacist. 
- Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom ali farmacevtom.
In some patients the development of YMDD mutant HBV can lead to exacerbation of hepatitis, primarily detected by serum ALT elevations and re-emergence of HBV DNA (see section 4.2). 
Pri nekaterih bolnikih lahko pojav YMDD mutanta HBV vodi do poslabšanja hepatitisa, kar se primarno zazna z zvišanjem serumske ALT in ponovnim pojavom HBV DNA (glejte poglavje 4.2).
In patients with compensated liver disease, these increases in serum ALT were generally not accompanied by an increase in serum bilirubin concentrations or signs of hepatic decompensation. 
Pri bolnikih s kompenzirano boleznijo jeter zvišanja serumske ALT na splošno ni bilo pri povečanju koncentracije bilirubina v serumu ali znakih dekompenzacije jeter.
In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48 % (28/58) and 47 % (15/32), respectively. 
V študiji podaljšanega zdravljenja pri bolnikih v Aziji (NUCB3018) je bil ob zaključku 5-letnega zdravljenja odstotek serokonverzije HBeAg 48 % (28/58), odstotek normalizacije ALT pa 47 %
Don't stop taking Zeffix without your doctor's advice, as there is a risk of your hepatitis getting worse. 
Ne prenehajte z jemanjem zdravila Zeffix, ne da bi se prej posvetovali z zdravnikom; obstaja namreč tveganje za poslabšanje hepatitisa.
Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues showed activity in an in vitro cytogenetic assay and the mouse lymphoma assay. 
Z bakterijskimi testi mutagenost lamivudina ni bila dokazana, vendar je podobno kot mnogi nukleozidni analogi pokazal aktivnost v in vitro citogenetskem testu in testu na mišjem limfomu.
In patients who do not maintain a sustained serological response, consideration should be given to retreatment with either lamivudine or an alternative antiviral agent for resumption of clinical control of HBV. 
Pri bolnikih, pri katerih se serološki odziv ni ohranil je potrebno razmisliti o ponovnem zdravljenju z lamivudinom ali uvedbi alternativnega protivirusnega zdravila, da bi se tako ponovno vzpostavila klinična nadzorovanost HBV.
If you forget to take Zeffix 
Če ste pozabili vzeti zdravilo Zeffix
- Week 260 normal above normal < baseline above normal > baseline 
- 260. teden normalna vrednost vrednost višja od normalne vrednosti < izhodiščna vrednost vrednost višja od normalne vrednosti > izhodiščna vrednost
The formation of further viral DNA is blocked by incorporation of lamivudine-TP into the chain and subsequent chain termination. 
Lamivudin-TP blokira nadaljnje nastajanje virusne DNA tako, da se vključi v verigo in s tem povzroči terminacijo verige.
• breakdown of muscle tissue 
• oslabelost mišičnega tkiva;
Cartons containing 240 ml lamivudine oral solution in an opaque, white, high-density polyethylene (HDPE) bottle with a polypropylene child resistant closure. 
Škatle, ki vsebujejo 240 ml peroralne raztopine lamivudina v neprosojnih, belih plastenkah iz polietilena visoke gostote (HDPE), z za otroke varno zaporko iz polipropilena.
In patients followed for up to 16 weeks after discontinuation of treatment at one year, post-treatment ALT elevations were observed more frequently in patients who had received lamivudine than in patients who had received placebo. 
Pri bolnikih, ki so bili po prekinitvi zdravljenja nadzirani do 16 tednov, je bilo zvišanje ALT eno leto po zdravljenju pogosteje opaženo pri bolnikih, ki so dobivali lamivudin, kot pa pri bolnikih, ki so dobivali placebo.
Reproductive studies in animals have not shown evidence of teratogenicity and showed no effect on male or female fertility. 
Študije vpliva na sposobnost razmnoževanja pri živalih niso podale dokazov o teratogenosti, pokazale pa so, da ne vpliva na plodnost samcev ali samic.
The active ingredient in Zeffix is lamivudine. 
Učinkovina v zdravilu Zeffix je lamivudin.
Don't take this medicine after the expiry date shown on the carton and blister. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli.
Administration of lamivudine at very high dose levels in acute animal studies did not result in any organ toxicity. 
Dajanje zelo velikih odmerkov lamivudina pri akutnih študijah na živalih ni vplivalo toksično na noben organ.
As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD mutant HBV after 52 weeks treatment was higher (36 % - 64 %) in the liver transplant population than in the immunocompetent CHB patients (14 % - 32 %). 
Kot je bilo pričakovano zaradi spremljajoče imunosupresije, je bil odstotek pojavnosti YMDD mutanta HBV po 52 tednih zdravljenja večji (36 do 64 %) pri bolnikih s transplantacijo jeter kot pa pri imunokompetentnih bolnikih s CHB (14 do 32 %).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding to albumin. 
Lamivudin kaže v območju terapevtskega odmerka linearno farmakokinetiko in nizko vezavo na plazemski protein albumin.
Data are limited on the use of lamivudine in HBeAg negative (pre-core mutant) patients and in those receiving concurrent immunosuppressive regimes, including cancer chemotherapy. 
Imunosupresivno zdravljenje Podatki o uporabi lamivudina pri HBeAg negativnih bolnikih (okuženih s pre-core mutanto) in pri tistih, ki imajo predpisano sočasno imunosupresivno zdravljenje, vključno s kemoterapijo rakavih obolenj, so omejeni.
• emtricitabine, used to treat HIV or hepatitis B infection 
• emtricitabin, ki se uporablja pri zdravljenju okužbe s HIV in pri okužbah s hepatitisom B,
Viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 with patients having continued improvement in virologic and biochemical responses. 
Supresija virusa se je (nadaljevalna študija NUC20917) s kombiniranim zdravljenjem med drugim letom zdravljenja ohranila do 104. tedna in bolniki so še naprej imeli izboljšanje virološkega in biokemičnega odziva.
Maternal hepatitis B is not a contraindication to breast-feeding if the newborn is adequately managed for hepatitis B prevention at birth, and there is no evidence that the low concentration of lamivudine in human milk leads to adverse reactions in breastfed infants. 
Hepatitis B pri materi ni kontraindikacija za dojenje, če je novorojenček ob rojstvu ustrezno voden glede preprečevanja hepatitisa B. Ni dokazov, da bi nizka koncentracija lamivudina v materinem mleku pri dojenčku povzročala neželene učinke.
For patients who are being treated with lamivudine and subsequently become pregnant consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine. 
Pri bolnicah, ki se zdravijo z lamivudinom in potem zanosijo, je treba upoštevati možnost za ponovitev hepatitisa po prenehanju uporabe lamivudina.
Clear, colourless to pale yellow in colour. 
peroralna raztopina Bistra, brezbarvna do bledo rumena.
This degree of viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 and most patients had improved markers of liver function and continued to derive clinical benefit. 
Ta stopnja supresije virusa se je (nadaljevalna študija NUC20917) s kombiniranim zdravljenjem med drugim letom zdravljenja ohranila do 104. tedna; večina bolnikov je imela izboljšane označevalce delovanja jeter in jim je zdravljenje še naprej klinično koristilo.
Five percent (3/56) of patients without the YMDD mutant and 13 % (11/82) of patients with YMDD mutant showed worsening in liver inflammation compared to pre-treatment. 
Pri petih odstotkih (3/56) bolnikov brez YMDD mutanta in 13 % (11/82) bolnikov z YMDD mutantom je prišlo do poslabšanja vnetnih sprememb v primerjavi s stanjem pred zdravljenjem.
The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea. 
Najpogosteje so poročali o naslednjih neželenih učinkih: slabem počutju in utrujenosti, infekcijah respiratornega trakta, neugodju v predelu grla in tonzil, glavobolu, neugodju in bolečinah v trebuhu, navzei, bruhanju in diareji.